​

Liminatus Pharma Stock (NASDAQ:LIMN)

FinancialsChart
Liminatus Pharma by TradingView

Previous Close

$0.24

52W Range

$0.21 - $33.66

50D Avg

$0.74

200D Avg

$3.96

Market Cap

$7.14M

Avg Vol (3M)

$8.42M

Beta

0.41

Div Yield

-

LIMN Company Profile

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

May 01, 2025

Website

LIMN Performance

LIMN Financial Summary

Dec 24
Revenue-
Operating Income$-405.00
Net Income$-405.00
EBITDA$-405.00
Basic EPS$-4.05
Diluted EPS$-4.05

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
DYAIDyadic International, Inc.
EVAXEvaxion Biotech A/S
MURAMural Oncology plc
JSPRJasper Therapeutics, Inc.
BTAIBioXcel Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
GBIOGeneration Bio Co.
ATHEAlterity Therapeutics Limited